Fig. 4From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II studyKaplan–Meier estimates for PFS in the axitinib- and placebo-titration arms stratified by OS. Patients were stratified by OS ≥24 vs. < 24 months. Abbreviations: CI confidence interval, mPFS median progression-free survival, NE not estimable, OS overall survivalBack to article page